Skip to main content
Erschienen in: Strahlentherapie und Onkologie 3/2020

26.09.2019 | Original Article

Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis

verfasst von: Luca Nicosia, Ciro Franzese, Rosario Mazzola, Davide Franceschini, Michele Rigo, Giuseppe D’agostino, Stefanie Corradini, Filippo Alongi, Marta Scorsetti

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

For patients with oligometastatic/oligorecurrent/oligoprogressive lymph node metastases from PCa, metastases-directed therapy is an emerging strategy. The aim of this retrospective study was to evaluate the oncological outcome and pattern of recurrence in patients treated with stereotactic body radiation therapy (SBRT) to lymph node metastases.

Methods

In this multi-institutional analysis, patients with a maximum of five lymph node metastases from PCa treated with SBRT were included. Primary endpoints of the analysis were local control (LC), out-of-field nodal progression-free survival (NPFS), overall progression-free survival (PFS), and overall survival (OS).

Results

109 patients and 155 lymph node metastases were evaluated. Patients’ median age was 70.8 years (range 51–84) and median PSA before SBRT was 1.88 ng/ml (range 0.3–45.5 ng/ml). The dose delivered to the target ranged from 25 to 48 Gy in 4–7 fractions; median BED1.5Gy was 198 Gy (range 108.3–432 Gy). With a median follow-up of 16 months, LC rates at 1 and 3 years were 93% and 86%, respectively. In-field progression of disease was observed in 11 (7%) lesions. One- and 3‑year NPFS was 59% and 29%, and median NPFS was 15 months. Rates of OS at 1 and 3 years were 100% and 95%. The median time to administration of a systemic treatment after SBRT was 7.8 months (1.7–54.8).

Conclusion

SBRT is an effective and well-tolerated treatment option in the management of lymph node metastases from PCa. Prospective trials are necessary to better select patients who benefit most from this ablative focal treatment and better define the recurrence patterns.
Literatur
1.
Zurück zum Zitat Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M (2015) Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol 68(2):325–334 (Aug)CrossRef Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M (2015) Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol 68(2):325–334 (Aug)CrossRef
2.
Zurück zum Zitat Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, Carta G, Livi L, Santoni R. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol. 2018 Oct 30. pii: S0093-7754(17)30050‑7. Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, Carta G, Livi L, Santoni R. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol. 2018 Oct 30. pii: S0093-7754(17)30050‑7.
3.
Zurück zum Zitat Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O’Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate Group (2015) Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS. The evolutionary history of lethal metastatic prostate cancer. Nature 16;520(7547):353–357 (Apr)CrossRef Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O’Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate Group (2015) Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS. The evolutionary history of lethal metastatic prostate cancer. Nature 16;520(7547):353–357 (Apr)CrossRef
4.
Zurück zum Zitat Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ, Prostate Cancer Clinical Trials Working Group 3. Trial Design and Objectives for Castration-Resistant Prostate Cancer (2016) Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 20;34(12):1402–1418 (Apr)CrossRef Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ, Prostate Cancer Clinical Trials Working Group 3. Trial Design and Objectives for Castration-Resistant Prostate Cancer (2016) Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 20;34(12):1402–1418 (Apr)CrossRef
5.
Zurück zum Zitat Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy LA, Lock MI, Rodrigues G, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Liu MC, Moore K, Currie S, Bauman GS, Warner A, Senan S (2018) Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial. Int J Radiol Oncol Biol Phys 102(3):S3–S4. https://doi.org/10.1016/j.ijrobp.2018.06.105 CrossRef Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy LA, Lock MI, Rodrigues G, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Liu MC, Moore K, Currie S, Bauman GS, Warner A, Senan S (2018) Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial. Int J Radiol Oncol Biol Phys 102(3):S3–S4. https://​doi.​org/​10.​1016/​j.​ijrobp.​2018.​06.​105 CrossRef
6.
Zurück zum Zitat Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR (2016) Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys 1;95(2):696–702 (Jun)CrossRef Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR (2016) Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys 1;95(2):696–702 (Jun)CrossRef
7.
Zurück zum Zitat De Bari B, Alongi F, Buglione M, Campostrini F, Briganti A, Berardi G, Petralia G, Bellomi M, Chiti A, Fodor A, Suardi N, Cozzarini C, Nadia DM, Scorsetti M, Orecchia R, Montorsi F, Bertoni F, Magrini SM, Jereczek-Fossa BA. Salvage therapy of small volume prostate cancer nodal failures: a review of the literature. Crit Rev Oncol Hematol. 2014 Apr;90(1):24–35. https://doi.org/10.1016/j.critrevonc.2013.11.003. Epub 2013 Nov 21. Review. PubMed PMID: 24315428.CrossRef De Bari B, Alongi F, Buglione M, Campostrini F, Briganti A, Berardi G, Petralia G, Bellomi M, Chiti A, Fodor A, Suardi N, Cozzarini C, Nadia DM, Scorsetti M, Orecchia R, Montorsi F, Bertoni F, Magrini SM, Jereczek-Fossa BA. Salvage therapy of small volume prostate cancer nodal failures: a review of the literature. Crit Rev Oncol Hematol. 2014 Apr;90(1):24–35. https://​doi.​org/​10.​1016/​j.​critrevonc.​2013.​11.​003. Epub 2013 Nov 21. Review. PubMed PMID: 24315428.CrossRef
10.
Zurück zum Zitat Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, Maranzano E, Lohr F, D’Angelillo R, Magli A, Bonetta A, Mazzola R, Pasinetti N, Francolini G, Ingrosso G, Trippa F, Fersino S, Borghetti P, Ghirardelli P, Magrini SM (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 6;116(12):1520–1525 (Jun)CrossRef Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, Maranzano E, Lohr F, D’Angelillo R, Magli A, Bonetta A, Mazzola R, Pasinetti N, Francolini G, Ingrosso G, Trippa F, Fersino S, Borghetti P, Ghirardelli P, Magrini SM (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 6;116(12):1520–1525 (Jun)CrossRef
11.
Zurück zum Zitat Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, Muto M, Surgo A, Zerini D, Marvaso G, Timon G, Romanelli P, Rondi E, Comi S, Cattani F, Golino F, Mazza S, Matei DV, Ferro M, Musi G, Nolè F, de Cobelli O, Ost P, Orecchia R (2017) Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. Clin Genitourin Cancer 15(4):e623–e632CrossRef Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, Muto M, Surgo A, Zerini D, Marvaso G, Timon G, Romanelli P, Rondi E, Comi S, Cattani F, Golino F, Mazza S, Matei DV, Ferro M, Musi G, Nolè F, de Cobelli O, Ost P, Orecchia R (2017) Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. Clin Genitourin Cancer 15(4):e623–e632CrossRef
12.
Zurück zum Zitat Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, Briganti A (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852–863 (May)CrossRef Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, Briganti A (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852–863 (May)CrossRef
13.
Zurück zum Zitat Berkovic P, De Meerleer G, Delrue L et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 11:27–32CrossRef Berkovic P, De Meerleer G, Delrue L et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 11:27–32CrossRef
14.
Zurück zum Zitat Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G (2018) Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 10;36(5):446–453 (Feb)CrossRef Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G (2018) Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 10;36(5):446–453 (Feb)CrossRef
15.
Zurück zum Zitat Alongi F, Fogliata A, Clerici E, Navarria P, Tozzi A, Comito T, Ascolese AM, Clivio A, Lobefalo F, Reggiori G, Cozzi L, Mancosu P, Tomatis S, Scorsetti M (2012) Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol 5;7:204 (Dec)CrossRef Alongi F, Fogliata A, Clerici E, Navarria P, Tozzi A, Comito T, Ascolese AM, Clivio A, Lobefalo F, Reggiori G, Cozzi L, Mancosu P, Tomatis S, Scorsetti M (2012) Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol 5;7:204 (Dec)CrossRef
18.
Zurück zum Zitat Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O’Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR, Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. (2012) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018 Dec 1;392(10162):2353–2366. Oncol 5;7:204 (Dec) Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O’Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR, Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. (2012) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018 Dec 1;392(10162):2353–2366. Oncol 5;7:204 (Dec)
20.
Zurück zum Zitat De Bruycker A, De Bleser E, Decaestecker K, Fonteyne V, Lumen N, De Visschere P, De Man K, Delrue L, Lambert B, Ost P (2018) Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. Eur Urol. Nov 28. pii: S0302-2838(18)30839‑X. De Bruycker A, De Bleser E, Decaestecker K, Fonteyne V, Lumen N, De Visschere P, De Man K, Delrue L, Lambert B, Ost P (2018) Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. Eur Urol. Nov 28. pii: S0302-2838(18)30839‑X.
21.
Zurück zum Zitat Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F, Draghini L, Di Murro L, Lancia A, Santoni R (2017) Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol 35(1):45–49 (Jan)CrossRef Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F, Draghini L, Di Murro L, Lancia A, Santoni R (2017) Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol 35(1):45–49 (Jan)CrossRef
22.
Zurück zum Zitat Franzese C, Zucali PA, Di Brina L, D’Agostino G, Navarria P, Franceschini D, Santoro A, Scorsetti M (2018) Cancer The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Med 7(9):4379–4386 (Sep) Franzese C, Zucali PA, Di Brina L, D’Agostino G, Navarria P, Franceschini D, Santoro A, Scorsetti M (2018) Cancer The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Med 7(9):4379–4386 (Sep)
23.
Zurück zum Zitat Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, Orecchia R, Casamassima F, Surgo A, Miralbell R, De Meerleer G (2016) Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. Clin Oncol (r Coll Radiol) 28(9):e115–20 (Sep)CrossRef Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, Orecchia R, Casamassima F, Surgo A, Miralbell R, De Meerleer G (2016) Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. Clin Oncol (r Coll Radiol) 28(9):e115–20 (Sep)CrossRef
24.
Zurück zum Zitat De Bari B, Alongi F, Lestrade L, Giammarile F (2014) Choline-PET in prostate cancer management: the point of view of the radiation oncologist. Crit Rev Oncol Hematol 91(3):234–247 (Sep)CrossRef De Bari B, Alongi F, Lestrade L, Giammarile F (2014) Choline-PET in prostate cancer management: the point of view of the radiation oncologist. Crit Rev Oncol Hematol 91(3):234–247 (Sep)CrossRef
25.
Zurück zum Zitat Walacides D, Meier A, Knöchelmann AC, Meinecke D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, von Klot CAJ, Christiansen H, Henkenberens C (2019) Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer. Strahlenther Onkol. Comparison 6(8):4 Walacides D, Meier A, Knöchelmann AC, Meinecke D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, von Klot CAJ, Christiansen H, Henkenberens C (2019) Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer. Strahlenther Onkol. Comparison 6(8):4
27.
Zurück zum Zitat Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O’Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG (2018) Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol 19(12):e696–e708CrossRef Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O’Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG (2018) Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol 19(12):e696–e708CrossRef
28.
Zurück zum Zitat Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L (2015) Prospective Comparison of 18F-Fluoromethylcholine Versus 68 Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med 56(8):1185–1190 (Aug)CrossRef Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L (2015) Prospective Comparison of 18F-Fluoromethylcholine Versus 68 Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med 56(8):1185–1190 (Aug)CrossRef
29.
Zurück zum Zitat Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C (2017) Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 44(1):92–101 (Jan)CrossRef Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C (2017) Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 44(1):92–101 (Jan)CrossRef
30.
Zurück zum Zitat Detti B, D’Angelillo RM, Ingrosso G, Olmetto E, Francolini G, Triggiani L, Bruni A, Borghesi S, Fondelli S, Carfagno T, Santini R, Santoni R, Trodella LE, Livi L (2017) Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy. Anticancer Res 37(7):3717–3722 (Jul)PubMed Detti B, D’Angelillo RM, Ingrosso G, Olmetto E, Francolini G, Triggiani L, Bruni A, Borghesi S, Fondelli S, Carfagno T, Santini R, Santoni R, Trodella LE, Livi L (2017) Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy. Anticancer Res 37(7):3717–3722 (Jul)PubMed
Metadaten
Titel
Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis
verfasst von
Luca Nicosia
Ciro Franzese
Rosario Mazzola
Davide Franceschini
Michele Rigo
Giuseppe D’agostino
Stefanie Corradini
Filippo Alongi
Marta Scorsetti
Publikationsdatum
26.09.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 3/2020
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-019-01523-9

Weitere Artikel der Ausgabe 3/2020

Strahlentherapie und Onkologie 3/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.